CERo Therapeutics Holdings, Inc. (CERO)
- Previous Close
0.5837 - Open
0.5682 - Bid 0.5570 x 500
- Ask 0.6129 x 500
- Day's Range
0.5617 - 0.5967 - 52 Week Range
0.5340 - 117.0000 - Volume
376,746 - Avg. Volume
1,818,962 - Market Cap (intraday)
3.264M - Beta (5Y Monthly) 0.68
- PE Ratio (TTM)
-- - EPS (TTM)
-40.2900 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.00
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
www.cero.bioRecent News: CERO
View MorePerformance Overview: CERO
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CERO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CERO
View MoreValuation Measures
Market Cap
3.22M
Enterprise Value
4.65M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-178.66%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-11.09M
Diluted EPS (ttm)
-40.2900
Balance Sheet and Cash Flow
Total Cash (mrq)
3.25M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-3.66M